Preparing For The Zero Moment Of Truth: Managing Early Awareness In Rare Disease Drug Commercialization
Awareness of new rare disease drugs develops much earlier than traditional therapies. Biopharma companies need to provide and actively manage information to the many stakeholders interested in new products’ progress and potential.
You may also be interested in...
For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.
Hard-won experience from the first wave of broad-market biosimilars will inform development of "orphan biosimilars," but Navigant Consulting says that biopharmas entering this orphan market will face a unique set of challenges.